Evaluation of the Swedish adjustable gastric band VC (SAGB-VC) in an Australian population: early results

Evaluation of the Swedish adjustable gastric band VC (SAGB-VC) in an Australian population: early results

Can J Surg 2013;56(1):15-20 | Full Text | PDF

Jennifer B. Keogh, PhD*†; Anthony Brancatisano, PhD‡; Sue F. Taylor, MBBS§; Fiona McDonald, BHSci*; Roy Brancatisano, MBBS‡; Jeffrey M. Hamdorf, PhD§; Jacob Chisholm, MBBS*; Lillian Kow, PhD*¶; Sara Wahlroos, MBBS‡; Brendan Ryan, MBBS‡; Jim Toouli, PhD*¶

From the *Australian Institute of Weight Control, Adelaide, the †School of Pharmacy & Medical Sciences & Sansom Institute for Health Research, Division of Health Sciences, University of South Australia, Adelaide, the ‡Australian Institute of Weight Control, Sydney, the §Australian Institute of Weight Control, Perth, and the School of Surgery, The University of Western Australia, Crawley, and the ¶Department of Surgery, Flinders University, Adelaide, Australia

Abstract

Background: The Swedish adjustable gastric band VC (SAGB-VC) has been in use in Australia since 2007. We evaluated its efficacy and safety.

Methods: We retrospectively analyzed the prospective clinical data of patients who received the implant between November 2007 and June 2009 at 3 Australian bariatric centres.

Results: In all, 1176 patients (mean age 45.9 [standard deviation (SD) 12.3] yr, mean body mass index 43.4 [SD 7.6]) received the SAGB-VC. At a mean follow-up of 11 (SD 3) months, weight reduced by a mean of 18.4 (SD 11.1) kg with an excess weight loss of 37.8% (SD 19.9%). Body mass index decreased (from mean 43.4 [SD 7.7] to mean 36.7 [SD 6.5], p < 0.001). Type 2 diabetes (T2DM) was reported in 167 patients and hypertension in 373. Improvement occurred in 73.5% of patients with T2DM and 31% with hypertension, with patient-reported reduction or cessation of medication. Metabolic syndrome indices improved during follow-up: high-density lipoprotein cholesterol (mean 1.3 [SD 0.3] v. mean 1.4 [SD 0.3] mmol/L, p < 0.001), triglycerides (mean 1.6 [SD 0.8] v. mean 1.3 [SD 0.7] mmol/L, p < 0.001), waist circumference (men 141 [SD 103] to 121 [SD 15] cm, women 117 [SD 14] to 105 [SD 14] cm, both p < 0.001), C-reactive protein (90.5 [SD 75.2] v. 53.3 [SD 61.9] nmol/L, p < 0.001). The complication rate was 4.2%. Conclusion: The SAGB-VC is safe and effective for treating obesity and its comorbidities. The results are reproducible in separate Australian centres and consistent with published literature.

Résumé

Contexte : On utilise l’anneau gastrique ajustable suédois VC (AGAS-VC) depuis 2007. Nous avons évalué son efficacité et son innocuité.

Méthodes : Nous avons analysé de manière rétrospective les données cliniques prospectives concernant les patients ayant reçu l’implant entre novembre 2007 et juin 2009 dans 3 centres bariatriques australiens.

Résultats : En tout, 1176 patients (âge moyen 45,9 [écart-type (ET) 12,3] ans, indice de masse corporelle moyenne 43,4 [ET 7,6]), ont reçu le dispositif AGAS-VC. Après un suivi moyen de 11 (ET 3) mois, le poids avait diminué en moyenne de 18,4 (ET 11,1) kg, avec une perte d’exédent de poids de 37,8 % (ET 19,9 %). L’indice de masse corporelle a diminué (d’une moyenne de 43,4 [ET 7,7] à une moyenne de 38,7 [ET 6,5], p < 0,001). Le diabète de type 2 (DT2) avait été signalé chez 167 patients et l’hypertension, chez 373 patients. On a observé une amélioration chez 73,5 % des patients atteints de DT2 et chez 31 % des patients atteints d’hypertension, avec réduction ou arrêt des médicaments déclarés par les patients. Les indices de syndrome métabolique se sont améliorés durant le suivi : cholestérol à lipoprotéines de haute densité (moyenne 1,3 [ET 0,3] c. moyenne 1,4 [ET 0,3] mmol/L, p < 0,001), triglycérides (moyenne 1,6 [ET 0,8] c. moyenne 1,3 [ET 0,7] mmol/L, p < 0,001), tour de taille (hommes, de 141 [ET 103] à 121 [ET 15] cm; femmes, de 117 [ET 14] à 105 [ET 14] cm, tous p < 0,001), protéine C réactive (90,5 [ET 75,2] c. 53,3 [ET 61,9] nmol/L, p < 0,001). Le taux de complications a été de 4,2 %. Conclusion : Le dispositif AGAS-VC est sécuritaire et efficace pour le traitement de l’obésité et de ses comorbidités. Les résultats sont reproductibles dans différents centres australiens et concordent avec les résultats publiés dans la littérature.


Accepted for publication June 14, 2011

Funding: This was an investigator-initiated study. Partial financial support was provided by Ethicon Endo-Surgery Inc. Grant No. 2925

Competing interests: None declared for J.B. Keogh, S. Taylor and S.Wahlroos. As above for A. Brancatisano, F. McDonald, R. Brancatisano, J. Chisholm, L. Kow, B. Ryan and J. Toouli. J.M. Hamdorf declares having received consultancy fees from Allergan and travel assistance from Johnson and Johnson.

Contributors: J.B. Koegh, A. Bransatisano, R. Brancatisano, L. Kow, B. Ryan and J. Toouli designed the study. J.B. Koegh, A. Bransatisano, S.Taylor, F. McDonald, J.M. Hamdorf, L. Kow and S. Wahlroos undertook data extraction. J.B. Koegh, A. Bransatisano, F. McDonald, J.M. Hamdorf, J. Chisholm and J. Toouli undertook data analysis. J.B. Koegh and J. Toouli wrote the manuscript. All authors critically reviewed it and approved publication..

DOI: 10.1503/cjs.011511

Correspondence to: J. Keogh, School of Pharmacy & Medical Sciences, Sansom Institute for Health Research, Division of Health Sciences, University of South Australia, Adelaide, Australia; jennifer.keogh@unisa.edu.au